This is the authors’ response to peer-review reports for “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis.” This evidence concerns the gene GLP1R and neoplasm.